A conformational sensor based on genetic code expansion reveals an autocatalytic component in EGFR activation. by Baumdick, Martin et al.
ARTICLE
A conformational sensor based on genetic code
expansion reveals an autocatalytic component in
EGFR activation
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Epidermal growth factor receptor (EGFR) activation by growth factors (GFs) relies on
dimerization and allosteric activation of its intrinsic kinase activity, resulting in trans-
phosphorylation of tyrosines on its C-terminal tail. While structural and biochemical studies
identiﬁed this EGF-induced allosteric activation, imaging collective EGFR activation in cells
and molecular dynamics simulations pointed at additional catalytic EGFR activation
mechanisms. To gain more insight into EGFR activation mechanisms in living cells, we
develop a Förster resonance energy transfer (FRET)-based conformational EGFR indicator
(CONEGI) using genetic code expansion that reports on conformational transitions in the
EGFR activation loop. Comparing conformational transitions, self-association and auto-
phosphorylation of CONEGI and its Y845F mutant reveals that Y845 phosphorylation induces
a catalytically active conformation in EGFR monomers. This conformational transition
depends on EGFR kinase activity and auto-phosphorylation on its C-terminal tail, generating
a looped causality that leads to autocatalytic ampliﬁcation of EGFR phosphorylation at low
EGF dose.
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D imerization of EGFR by GFs activates its intrinsic kinaseactivity, which trans-phosphorylates tyrosine residues onthe C-terminal receptor tail1,2. SH2- or PTB-containing
signal transducing proteins are then recruited to these phos-
phorylated tyrosines, propagating the signal in the cytoplasm3,4.
Structural data of EGFR indicate that in absence of ligand, a
closed tethered extracellular domain (ECD) and association of the
intracellular tyrosine kinase domain (TKD) with the negatively
charged plasma membrane (PM) by two polybasic stretches favor
steric auto-inhibition of EGFR’s intrinsic kinase activity5–7.
Ligand binding to EGFR is coupled to conformational changes in
the extra- and intracellular domains and overcomes intrinsic
auto-inhibition resulting in allosteric activation via asymmetric
dimer formation of the TKD2,5. For this, the αC-helix located in
the N-lobe of the TKD moves from its out-conﬁguration to
an ordered in-conﬁguration, while the activation loop frees the
catalytic cleft and undergoes conformational rearrangements of
~20 Å8–10. Despite the steric auto-inhibitory features, autono-
mous EGFR phosphorylation was observed in several cancer
types including breast and lung cancer that either exhibit high
EGFR surface concentrations through EGFR overexpression or
bear oncogenic mutations favoring an active conformation9,11–13.
Spontaneous auto-phosphorylation of unliganded EGFR can
occur due to thermal ﬂuctuations that overcome intrinsic steric
auto-inhibition14–16. These auto-phosphorylation events can
trigger an autocatalytic ampliﬁcation mechanism when they
induce an active conformation that further catalyzes EGFR auto-
phosphorylation15. Molecular dynamics simulations suggested
that Y845 phosphorylation in the EGFR activation loop suppresses
intrinsic disorder in the αC-helix, thereby stabilizing an active
receptor conformation as well as increasing EGFR dimerization9.
We therefore investigate whether EGFR can adopt an active
conformation upon Y845 phosphorylation and how this impacts
on collective EGFR phosphorylation dynamics in living cells. A
clear avenue to obtain a better insight in collective EGFR acti-
vation is to monitor conformational dynamics of the TKD. For
this, we engineer a FRET-based conformational EGFR indicator
(CONEGI) using genetic code expansion. In contrast to existing
kinase activity sensors based on substrate phosphorylation17,
CONEGI is designed to report on conformational transitions in a
functional domain of the EGFR TKD by the change in distance
and orientation of a ﬂuorophore conjugated to an unnatural
amino acid (UAA) relative to the ﬂuorescent protein mCitrine
inserted into a conformationally invariant region. Based on
structural data, we identify the end of the TKD as an insertion site
for mCitrine that is conformationally invariant and does not
affect EGFR function. UAA incorporation and subsequent site-
speciﬁc labeling at position 851 creates a FRET-based sensor that
reports on conformational transitions of the EGFR activation
loop. This construct retains EGFR dimerizing and catalytic
functionality. Monitoring conformational transitions together
with dimerization and auto-phosphorylation and comparing
these readouts to a CONEGI Y845F mutant reveals that an active
conformation in monomeric receptors is induced by Y845 phos-
phorylation. We then show that Y845 phosphorylation depends on
auto-phosphorylation of the C-terminal tail, which creates an
autocatalytic loop that ampliﬁes EGFR phosphorylation at low,
non-saturating EGF concentrations.
Results
Design and performance of CONEGI. To monitor conforma-
tional states of the TKD, we engineered multiple FRET-based
conformational EGFR sensor variants, in which the donor,
monomeric Citrine (mCitrine), was always genetically encoded at
the same rigid region of the TKD and genetic code expansion and
bioorthogonal labeling chemistry were used to position the
acceptor, Atto590, at different, ﬂexible structures of the TKD that
change conformation upon activation (Fig. 1a). This hybrid
sensor design allows measuring structural changes in different key
functional TKD regions relative to the donor. Conformational
movements of these TKD regions will alter the distance and angle
between mCitrine and Atto590 resulting in changes in FRET
efﬁciency, which can be quantiﬁed by ﬂuorescence lifetime ima-
ging microscopy (FLIM). mCitrine was selected as donor because
of its mono-exponential ﬂuorescence decay proﬁle18,19 and the
membrane-permeable Atto590 as acceptor because of its high
extinction coefﬁcient (ε: 120,000), high quantum yield (QY: 0.8),
and spectral overlap with mCitrine (R0= 5.9 nm).
By aligning active (red; PDB: 2J5F) and inactive (cyan; PDB:
2GS7) crystal structures of the EGFR TKD (Fig. 1b), we identiﬁed a
conformationally invariant region at the TKD end, where we
inserted mCitrine between amino acids (aa) Q958 and G959 (EGFR-
QG-mCitrine)15. This site is exposed to the protein surface and not
part of the asymmetric as well as the symmetric dimerization
interface or regions known to be essential for kinase activity
(Supplementary Fig. 1a). To further minimize perturbation of the
TKD structure and constrain the mCitrine orientation, we used
two linkers that form an antiparallel coiled-coil helix for mCitrine
insertion20. EGFR-QG-mCitrine was fully active and correctly
localized as apparent from its similar localization and EGF-induced
phosphorylation as compared to C-terminally tagged EGFR
(EGFR-mCitrine) (Fig. 1c; Supplementary Fig. 1b, c), which was
shown to follow the localization and activity of endogenous
EGFR21,22. We then selected three regions (kinase loop 2, αC-helix,
and activation loop) that showed substantial differences between
the active and inactive conformation for Atto590 attachment
(Fig. 1b). We replaced the coding sequences of amino acids K713 in
the kinase loop 2, K730 and D737 in the αC-helix and K843 and K851
in the activation loop with an amber codon and also inserted an
amber codon between the coding sequence for E712 and K713. This
resulted in the creation of a series of EGFR(TAGXXX)-QG-
mCitrine variants, where XXX indicates the amber codon position.
We estimated the distances between the QG site that included the
maximum linker length and each proposed site of Atto590
attachment. The obtained distances (R) of ~7.4–8.5 nm were
sufﬁciently close to the Förster radius (R0= 5.9 nm) of the
employed FRET pair resulting in estimated FRET efﬁciencies
(EFRET) between 10 and 21% for the different variants as calculated
by EFRET ¼ R
6
0
R60þR6 (Supplementary Table 1). This showed that the
851 site yielded the highest (21%) FRET efﬁciency. We conjugated
Atto590 to the desired site in the TKD in a two-step process to
generate conformational EGFR indicators (CONEGIs): ﬁrst, we
used a derivative of the pyrrolylsyl-tRNA synthetase/tRNACUA pair
from Methanosarcina mazei to express each EGFR(TAGXXX)-
QG-mCitrine gene and direct the incorporation of added UAA
bicyclo[6.1.0]nonyne-lysine (BCNK)23,24; second, we labeled each
EGFR(BCNKXXX)-QG-mCitrine variant, where XXX indicates
the position of BCNK incorporation, with a tetrazine-Atto590 (tet-
Atto590) conjugate via an inverse electron demand Diels–Alder
reaction.
Expression of EGFR(BCNKXXX)-QG-mCitrine variants in
HEK293T cells was dependent on BCNK (Fig. 1d). Whereas
EGFR(BCNK851)-QG-mCitrine was expressed at a comparable
level to EGFR-QG-mCitrine, all other variants exhibited reduced
expression (Fig. 1d). EGFR(BCNKXXX)-QG-mCitrine labeling
with tet-Atto590 was selective, as judged by both, ﬂuorescence
imaging of cell lysates following SDS-PAGE, and co-localization
of mCitrine and Atto590 ﬂuorescence at the PM and intracellular
compartments as visualized in living cells by confocal micro-
scopy (Fig. 1d, e). All EGFR(BCNKXXX)-QG-mCitrine variants
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exhibited a similar localization as compared to an EGFR variant
C-terminally tagged with mTurquoise (EGFR-mTurquoise)
(Supplementary Fig. 1d). In addition to their comparable PM
distribution (Supplementary Fig. 1d, e), all CONEGI constructs
exhibited pericentriolar localization similar to EGFR-
mTurquoise. This pericentriolar compartment was identiﬁed to
be the Rab11-positive recycling endosome (Supplementary
Fig. 1f), which was previously shown to maintain EGFR at the
PM by continuous recycling15,25.
To experimentally determine whether EGFR(BCNKXXX)-QG-
mCitrine labeling with Atto-590 results in FRET, we imaged the
ﬂuorescence lifetime (τ) of mCitrine at the PM after addition of
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tet-Atto590 to living cells by FLIM. For all CONEGIs, we
obtained a signiﬁcant decrease in τ of mCitrine from 3.02 ± 0.004
ns (SEM) to 2.67 ± 0.039 ns (SEM) over a 20 min time course,
corresponding to an average EFRET between 10 and 14% as
calculated by: EFRET ¼ 1 τDAτD , where Atto590 conjugation to
BCNK incorporated into the 851 site yielded the highest FRET
efﬁciency (14.3 ± 0.8% (SEM)) (Fig. 1f, g). These experimental
EFRET values were in broad agreement with the theoretical
predictions, exhibiting equal or lower values possibly due to the
relative orientation between the dyes, which affects the parameter
κ2 in R0 (Supplementary Table 1, Fig. 1g). CONEGI-712/713
exhibited the fastest labeling kinetics, with a reaction time clearly
below 5min, which likely reﬂects the high accessibility of this site
for ﬂuorophore attachment (Fig. 1g). The drop in τ of mCitrine
associated with tet-Atto590 conjugation was reversed for all
CONEGIs upon Atto590 photobleaching (Supplementary Fig. 1g,
h). Furthermore, tet-Atto590 addition to cells co-expressing
EGFR-QG-mCitrine and the BCNK incorporation system in
presence of BCNK did not lead to an alteration in τ of mCitrine
(Fig. 1g, h). This demonstrated that the obtained changes in τ in
the CONEGIs result from speciﬁc FRET between mCitrine and
Atto590 conjugated to site-speciﬁcally incorporated BCNK and
not from tet-Atto590 non-speciﬁcally bound to EGFR or the PM,
or from labeling of BCNK that might be incorporated at genomic
amber codons. Washout of unbound tet-Atto590 after labeling of
cells did not abolish the decrease in τ of mCitrine for the
CONEGIs, conﬁrming that the conjugation of tet-Atto590 to
BCNK is stable (Supplementary Fig. 1i). The negative correlation
of τ with the Atto590 ﬂuorescence intensity and the saturation of
the binding curves at high Atto590 concentrations for all
CONEGIs further conﬁrmed speciﬁcity of tet-Atto590-
conjugation to BCNK in EGFR (Fig. 1h).
CONEGI-851 reports on activation loop conformations. To
investigate whether the CONEGIs report on conformational
changes in the TKD that occur upon activation, we measured τ of
mCitrine at the PM by FLIM following stimulation with EGF to
cells. We observed a signiﬁcant decrease in τ of CONEGI-737,
-843, and -851 and a signiﬁcant increase in τ of CONEGI-712/713
upon EGF stimulation, whereas τ of CONEGI-713 and -730 did
not signiﬁcantly change (Fig. 2a; Supplementary Fig. 2a). To
account for the variability in the completeness of the Atto590
labeling reaction that affects the initial FRET efﬁciency in a
particular CONEGI construct, the difference in τ (Δτ) relative to
the τ before stimulation in each experiment was plotted (Fig. 2b).
This Δτ-time plot that follows the general trends of the τ-time
plot (Supplementary Fig. 2a) clearly reﬂects the conformational
transitions of the CONEGI constructs. Neither τ of EGFR-QG-
mCitrine in presence of tet-Atto590 nor τ of EGFR(BCNK851)-
QG-mCitrine in absence of tet-Atto590 did change upon EGF
addition, precluding photophysical effects that change τ of
mCitrine upon EGF stimulation (Fig. 2b; Supplementary Fig. 2b).
To examine whether the EGFR(BCNKXXX)-QG-mCitrine
variants retain their activity upon BCNK incorporation, we
quantiﬁed the phosphorylation on tyrosines 1086 (Y1086) and
1148 (Y1148) by measuring the interaction of mCherry-tagged
phosphotyrosine-binding domain (PTB-mCherry) with each
EGFR(BCNK)-QG-mCitrine variant upon EGF stimulation by
FLIM26. EGF-induced PTB-mCherry recruitment to EGFR
(BCNK843)-QG-mCitrine and EGFR(BCNK851)-QG-mCitrine
at the PM resulted in a corresponding drop in τ (Fig. 2c, d). This
decrease in τ was comparable to that of EGFR-QG-mCitrine
upon EGF-mediated PTB-mCherry recruitment, whereas EGF-
induced phosphorylation of other variants (712/713, 713, 730,
and 737) only marginally increased as judged by minimal
decreases in τ of mCitrine (Fig. 2d). To examine whether other
phosphorylation sites were affected by BCNK incorporation and
Atto590 labeling, we quantiﬁed the relative phosphorylation (pY/
EGFR) on the Grb2-binding site Y106827 for all CONEGIs by
western blot analysis. Consistent with PTB-mCherry recruitment,
CONEGI-843 and -851 exhibited a similar EGF-induced fold-
change in Y1068 phosphorylation as compared to EGFR-QG-
mCitrine, but the relative phosphorylation level of CONEGI-843
was drastically reduced (Fig. 2e, f; Supplementary Fig. 2c). The
other CONEGIs showed increased autonomous phosphorylation
(CONEGI-712/713 and -713) or responded only marginally to
EGF (CONEGI-712/713, -713, -730 and -737), indicating that
their activation mechanism was impaired (Fig. 2e, f; Supplemen-
tary Fig. 2c). Immunoﬂuorescence staining against pY1068 in ﬁxed
HEK293T cells expressing EGFR(BCNK851)-QG-mCitrine
showed that EGF-mediated phosphorylation at the PM was
comparable to that of EGFR-QG-mCitrine (Fig. 2g; Supplemen-
tary Fig. 2d), which shows that EGFR(BCNK851)-QG-mCitrine
at the PM is fully functional. Tet-Atto590 labeling did not affect
autonomous or ligand-dependent EGFR phosphorylation of
EGFR(BCNK851)-QG-mCitrine (Supplementary Fig. 2e). We
therefore conclude that CONEGI-851 (from now on denoted as
CONEGI) most closely follows the native activation mechanism
of EGFR.
To investigate whether the change in FRET upon EGFR
activation detected in CONEGI is of intra- or intermolecular
origin, we measured τ of EGFR-QG-mCitrine (donor only) upon
co-expression with an EGFR(BCNK851) variant that was labeled
with Atto590 (acceptor only). τ of EGFR-QG-mCitrine in the
presence of Atto590-labeled EGFR(BCNK851) (2.992 ± 0.006
(SEM)) was close to that of EGFR-QG-mCitrine (3.033 ± 0.006
Fig. 1 Design and performance of CONEGI. a Schematic representation of CONEGI. mCitrine is fused to the C-terminal end of the tyrosine kinase domain
(TKD) using a coiled-coil linker (dashed line) and Atto590 (red star) is site-speciﬁcally attached to the activation loop. b Alignment of active (red; PDB:
2J5F) and inactive (cyan; PDB: 2GS7) crystal structures of the EGFR TKD. mCitrine insertion (QG, yellow) and BCNK incorporation sites (blue, black
arrows) are indicated. c Relative phosphorylation (PY72/EGFR) of EGFR-mCitrine or EGFR-QG-mCitrine upon EGF stimulation determined by western blot
analysis (n= 4; two-way analysis of variance (two-way ANOVA)) (Supplementary Fig. 1b). d Fluorescence images and western blot analysis following
SDS-PAGE of HEK293T cell lysates showing Atto590 ﬂuorescence and expression level of EGFR-QG-mCitrine and CONEGIs depending on BCNK. Blots
were probed with anti-EGFR and anti-Tubulin (left). Normalized relative EGFR expression (EGFR/Tub) (middle) and Atto590 ﬂuorescence intensity (right)
of EGFR-QG-mCitrine and CONEGIs (n= 3 blots). e Representative mCitrine and Atto590 ﬂuorescence images of EGFR-QG-mCitrine and CONEGIs in
HEK293T cells and corresponding green/magenta overlay. f Representative ﬂuorescence images of EGFR(BCNK851)-QG-mCitrine upon tetrazine-Atto590
labeling and corresponding τ. g Mean τ in CONEGIs and EGFR-QG-mCitrine (QG: n= 10 cells; 712/713: n= 8; 713: n= 6; 730: n= 11; 737: n= 7; 843: n=
10; 851: n= 17) at the PM upon tetrazine-Atto590 addition. h Dependency of τ in CONEGIs and EGFR-QG-mCitrine (QG: n= 42 cells; 712/713: n= 36; 713:
n= 43; 730: n= 36; 737: n= 30; 843: n= 44; 851: n= 32) on mean Atto590 ﬂuorescence intensity (F of Atto590) at the PM after 20min labeling. Data
points represent individual cells. τ, ﬂuorescence lifetime of mCitrine. Scale bars, 10 μm. EGF stimulation, 100 ngml−1. Error bars: SEM, except Fig. 1c: Tukey
box plot
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(SEM)) and only marginally decreased upon EGF stimulation
(Fig. 2h, i; Supplementary Fig. 2f), showing that FRET in CONEGI
reports on intramolecular conformational rearrangements. To
demonstrate that the change in FRET efﬁciency in CONEGI
originates from the rearrangement of the activation loop rather
than from mCitrine reorientation upon dimerization, we locked
the TKD into an inactive conformation using the ATP analog
EGFR inhibitor Lapatinib28. This abolished EGF-induced CON-
EGI phosphorylation (Supplementary Fig. 2g), but did not
prevent EGF-induced dimerization as measured by homo-FRET
between mCitrine using ﬂuorescence anisotropy29 (Fig. 2j;
Supplementary Fig. 2h). Importantly, this EGF-induced
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dimerization of CONEGI with a Lapatinib locked TKD
conformation did not result in a decrease in τ as observed for
CONEGI in absence of inhibitor (Fig. 2k). This shows that
CONEGI exclusively reports conformational transitions of the
activation loop, but not reorientation of mCitrine upon
dimerization.
A catalytic conformation by activation loop phosphorylation.
Phosphorylation of Y845 was previously described to affect both
the conformation of the EGFR TKD, and to enhance its dimer-
ization9. We therefore explored if Y845 phosphorylation in the
activation loop is linked to an EGFR conformational state that is
catalytically active without dimerization. For this, we compared
the dimerization and conformational transition of CONEGI upon
its ligand-independent phosphorylation to that of a CONEGI-
Y845F mutant. Ligand-independent phosphorylation of EGFR is
known to occur upon phosphatase inhibition by pervanadate
(PV)30 or upon high EGFR expression levels14,15,31,32. Under
both conditions, the intrinsic EGFR kinase activity surpasses the
reverse dephosphorylating activity of phosphatases, resulting in
an increased steady state phosphorylation level of EGFR15.
EGF administration at saturating dose (100 ng ml−1) resulted
in a drop in anisotropy of CONEGI (independent of UAA
incorporation or Atto590 labeling), showing EGF-induced
dimerization (Fig. 3a; Supplementary Fig. 3a, b). This
dimerization-induced drop in anisotropy could be affected by
the efﬁciency of UAA incorporation in response to the amber
stop codon, resulting in the expression of truncated CONEGI
(~43 ± 0.4% (SEM), Supplementary Fig. 3c). This truncated
CONEGI lacks the donor ﬂuorophore mCitrine, but potentially
could interact with full length CONEGI. We therefore
measured the amount of full length CONEGI at the PM by
determining the ﬂuorescence ratio of EGF-Alexa647 (100 ng
ml−1, binds to all CONEGI constructs) to mCitrine (only
expressed on full length CONEGI) (Supplementary Fig. 3d).
The identical ﬂuorescence ratio of EGFR(BCNK851)-QG-
mCitrine and full length EGFR-QG-mCitrine (Supplementary
Fig. 3d) showed that truncated CONEGI did not reach the PM.
The identical anisotropy responses to EGF of EGFR-QG-
mCitrine and unlabeled EGFR (BCNK851)-QG-mCitrine also
conﬁrmed that only full length CONEGI was present at the PM
(Supplementary Fig. 3a). The relatively smaller EGF-induced
change in anisotropy for CONEGI can be accounted for by the
~14.3 ± 0.8% (SEM) reduction in mCitrine ﬂuorescence lifetime
by FRET to Atto590.
EGF stimulation led to a concurrent increase in phosphoryla-
tion of Y1068 and Y845 (Fig. 3b, c; Supplementary Fig. 3e, f). In
contrast, the anisotropy of CONEGI did not change upon PV
treatment over a time course of 20 min, in which Y1068 and Y845
phosphorylation reached similar levels as compared to EGF
stimulation (Fig. 3a–c; Supplementary Fig. 3a, e, f). This
demonstrates that the majority of ligand-independent phos-
phorylated CONEGI is monomeric15,33. Both EGF and PV
induced a conformational change in CONEGI as apparent from
the decrease in τ. However, while EGF provoked a rapid drop in
τ, PV treatment resulted in a slower decrease in agreement with
the differential phosphorylation kinetics (Fig. 3b–d; Supplemen-
tary Fig. 3e–g). This shows that not only EGF-stimulated dimers
but also phosphorylated monomers undergo a conformational
change in the activation loop upon phosphorylation. For
CONEGI-Y845F expressing HEK293T cells, a signiﬁcantly
smaller and slower change in τ upon PV was observed showing
that Y845 phosphorylation induces a conformational change in
the activation loop (Fig. 3f; Supplementary Fig. 3h). This was
paralleled by a signiﬁcantly lower Y1068 auto-phosphorylation in
CONEGI-Y845F as compared to that of CONEGI, revealing that
Y845 phosphorylation results in a catalytically more active
CONEGI conformation (Fig. 3e; Supplementary Fig. 3i).
We next investigated the dependence of ligand-independent
phosphorylation on the expression level of CONEGI in relation
to the conformational transition of the activation loop. Exploit-
ing the cell-to-cell variance in mCitrine ﬂuorescence, allowed us
to relate CONEGI expression to phosphorylation on Y1068 as
measured by immunoﬂuorescence. We could clearly observe an
expression level-dependent increase in auto-phosphorylation
that was absent in its Y845F mutant (Fig. 3g, i; Supplementary
Fig. 3j). This increase in auto-phosphorylation was not due to an
increase in dimers at higher expression as apparent from the
ﬂuorescence anisotropy as function of CONEGI expression
(Supplementary Fig. 3a). In an analogous experiment, we related
CONEGI expression by its ﬂuorescence intensity to its
conformational state by ﬂuorescence lifetime in many individual
cells. Here, we could clearly observe a CONEGI expression level-
dependent conformational transition that was absent in the
CONEGI-Y845F mutant (Fig. 3h, i). Together, these data show
that CONEGI but not its Y845F mutant is able to activate other
CONEGI molecules via Y845 phosphorylation, resulting in
catalytic ampliﬁcation. In order to estimate at which EGFR
expression levels this spontaneous ampliﬁcation in EGFR
phosphorylation can occur, we determined the level of CONEGI
expression in relation to endogenous EGFR expression in non-
Fig. 2 CONEGI-851 reports on conformational changes in the activation loop. a Representative CONEGI-851 ﬂuorescence and corresponding τ images upon
EGF stimulation. b Change in Δτ of CONEGIs and EGFR-QG-mCitrine (QG: n= 5 cells; 712/713: n= 7; 713: n= 7; 730: n= 7; 737: n= 7; 843: n= 6; 851:
n= 31) at the PM upon EGF stimulation (Supplementary Fig. 2a: absolute τ). c Representative ﬂuorescence images of EGFR(BCNK851)-QG-mCitrine, PTB-
mCherry, and corresponding τ upon EGF stimulation. d Change in Δτ of EGFR-QG-mCitrine or EGFR(BCNKXXX)-QG-mCitrine variants (QG: n= 4 cells;
712/713: n= 6; 713: n= 8; 730: n= 8; 737: n= 5; 843: n= 6; 851: n= 6) at the PM upon EGF-mediated PTB-mCherry recruitment. e Relative Y1068
phosphorylation (pY1068/EGFR) of EGFR-QG-mCitrine and CONEGIs upon EGF stimulation by western blot analysis (n= 5; paired two-tailed t-test)
(Supplementary Fig. 2c). f Fold-change in Y1068 phosphorylation (5′EGF/pre) (quantiﬁed from e) versus Δτ upon PTB-mCherry recruitment (quantiﬁed
from d) for CONEGIs and EGFR-QG-mCitrine. g Relative Y1068 phosphorylation (pY1068/EGFR) of EGFR-QG-mCitrine (QG) and EGFR(BCNK851)-QG-
mCitrine (851) at the PM upon EGF stimulation by immunoﬂuorescence (851: pre: n= 72 cells; 5′ÉGF: n= 67: QG: pre: n= 73; 5′ÉGF: n= 74)
(Supplementary Fig. 2d). h τ of EGFR-QG-mCitrine in absence (QG; n= 6 cells) or presence of tetrazine-Atto590 (QG+Atto590; n= 9), EGFR-QG-
mCitrine co-expressed with Atto590-labeled EGFR(BCNK851) (QG+A-851+Atto590; n= 36) and CONEGI (n= 32; unpaired two-tailed t-test)
(Supplementary Fig. 2f). i Change in Δτ of CONEGI (n= 27 cells) or EGFR-QG-mCitrine co-expressed with Atto590-labeled EGFR(BCNK851) (n= 7) upon
EGF stimulation. j Mean mCitrine ﬂuorescence anisotropy of CONEGI upon EGF stimulation in presence or absence of 1 μM Lapatinib (Lap)
(Supplementary Fig. 2h) (N= 3 experiments; n= 21–26 ﬁelds of view/condition; unpaired two-tailed t-test). k τ of CONEGI at the PM upon EGF stimulation
in presence (left; n= 22 cells) or absence (right; n= 33) of 1 μM Lap (unpaired two-tailed t-test). Scale bars, 10 μm. EGF stimulation, 100 ngml−1. Error
bars: SEM, except Fig. 2e: Tukey box plot. τ ﬂuorescence lifetime of mCitrine
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tumorigenic epithelial MCF10A (~1 × 105 receptors/cell) and
epidermoid carcinoma A431 cells (~1 × 106 receptors/cell)34–36.
Comparison of EGF-Alexa647 binding to CONEGI in
HEK293T cells to that of endogenous EGFR in A431 and
MCF10A cells revealed that between ~2 × 105–5 × 105 CONEGIs
are expressed per cell (Supplementary Fig. 3k). Matching the
intensity distribution of the EGF-Alexa647 ﬂuorescence bound
to CONEGI to the distribution of mCitrine intensities of
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Fig. 3 Y845 phosphorylation induces an active conformation of EGFR monomers. a Mean mCitrine ﬂuorescence anisotropy of CONEGI upon EGF or
pervanadate (PV) treatment (Supplementary Fig. 3a, b) (N= 3 experiments; n= 30–47 ﬁelds of view/condition; unpaired two-tailed t-test). b, c
Normalized relative Y1068 (pY1068/CONEGI) (b) or pY845 phosphorylation (pY845/CONEGI) (c) of CONEGI upon EGF or PV treatment by western blot
analysis (n= 3) (Supplementary Fig. 3e, f). d Change in Δτ of CONEGI (upper panel) at the PM and the difference between EGF and PV treatment (ΔΔτ)
(lower panel) (EGF: n= 19 cells; PV: n= 6) (Supplementary Fig. 3g). e Normalized relative Y1068 phosphorylation (pY1068/CONEGI) of CONEGI or
CONEGI-Y845F upon PV treatment by western blot analysis (n= 3; unpaired two-tailed t-test) (Supplementary Fig. 3i). f Change in Δτ of CONEGI and
CONEGI-Y845F upon PV treatment (upper panel) and the difference (ΔΔτ) between CONEGI and CONEGI-Y845F (lower panel) (CONEGI: n= 6 cells;
Y845F: n= 8; two-way ANOVA) (Supplementary Fig. 3h). g Relative Y1068 phosphorylation (pY1068/EGFR) of CONEGI and CONEGI-Y845F at increasing
EGFR expression levels as measured by mCitrine intensity per cell (Fcit binned as follows: <230, 230–330, 330–430, >430) (CONEGI: n= 80 cells; Y845F:
n= 81; unpaired two-tailed t-test). h Mean τ in CONEGI and CONEGI-Y845F at increasing EGFR expression levels (n= 47 cells/variant; unpaired two-
tailed t-test). i Relative Y1068 phosphorylation (pY1068/EGFR) of CONEGI and CONEGI-Y845F versus their τ of mCitrine upon increasing expression levels
(Fcit < 230, 230–330, 330–430, >430; as indicated by increasing dot size). j Distribution of relative EGFR expression in MCF10A (n= 125 cells), A431 (n=
129), and CONEGI-expressing HEK293T cells (n= 80) as derived from ﬂuorescence histograms of EGF-Alexa647 binding per cell to the respective cell
lines (Supplementary Figure 3k). EGF stimulation, 100 ngml−1. PV treatment, 0,33 mM. Error bars: SEM. τ ﬂuorescence lifetime of mCitrine
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CONEGI obtained from the pY1068 immunoﬂuorescence
experiments, allowed us to estimate the CONEGI expression
level from mCitrine ﬂuorescence. This showed that spontaneous
phosphorylation occurs at all CONEGI expression levels but
strongly increases at 3.8 × 105–4.6 × 105 receptors per cell, which
falls within the lower range of endogenous EGFR expression in
A431 cells (Fig. 3j).
EGFR dimers can induce autocatalytic activation of monomers.
We next investigated whether ligand-induced EGFR dimers can
activate receptor monomers. At saturating EGF dose (100 ng
ml−1), all receptors are occupied with ligand and are activated
by the canonical dimerization mechanism. However, catalytic
ampliﬁcation can take place at sub-saturating EGF dose (20 ng
ml−1) because only a fraction of receptors will be occupied by
ligand (20–30%; estimated by the ratio of EGF-Alexa647/mCi-
trine ﬂuorescence at 20 ng/ml over 100 ng/ml EGF-Alexa647
per cell) (Supplementary Fig. 4a). We therefore compared
CONEGI and CONEGI-Y845F phosphorylation and con-
formational dynamics in cells that were stimulated with satur-
ating or sub-saturating EGF dose. Upon stimulation with
saturating EGF dose, CONEGI and CONEGI-Y845F exhibited
similar rapid Y1068 phosphorylation reaching comparable levels
(Fig. 4a; Supplementary Fig. 4b). CONEGI and CONEGI-Y845F
also exhibited similar activation loop dynamics as apparent
from the comparable change in τ over time (Fig. 4b; Supple-
mentary Fig. 4d). This is consistent with the activation loop
being rearranged to an open conformation in both CONEGI
and its Y845F mutant by the canonical allosteric dimerization
mechanism. A similar EGF-induced decrease in anisotropy for
CONEGI and CONEGI-Y845F conﬁrmed that Y845F mutation
does not affect its dimerization (Supplementary Fig. 4c).
However, upon stimulation of cells with sub-saturating EGF
dose, Y1068 phosphorylation of CONEGI reached within 1 min
~39 ± 9% (SEM) of that at saturating EGF dose to further increase
over time to ~72 ± 12% (SEM), showing a clear ampliﬁcation of
Y1068 phosphorylation over time. This ampliﬁcation was absent in
CONEGI-Y845F, which after rapid initial activation remained
stable at ~49 ± 7% (SEM) of that of CONEGI at saturating EGF
(Fig. 4c; Supplementary Fig. 4b). Strikingly, the change in τ of
CONEGI-Y845F upon sub-saturating EGF stimulation was
signiﬁcantly slower and of lesser magnitude as compared to that
of CONEGI, which was comparable to that at saturating EGF
(Fig. 4d; Supplementary Fig. 4e). This shows that EGF-activated
CONEGI dimers induce an active conformation in unliganded
CONEGI monomers by Y845 phosphorylation (Fig. 4e; Supple-
mentary Fig. 4f). The question remained if Y845 is directly
phosphorylated by the intrinsic kinase activity of EGFR or
whether this happens indirectly by recruitment or activation of
another tyrosine kinase that is dependent on C-terminal tyrosine
auto-phosphorylation of EGFR. It was previously shown that Y to
A mutation of the Y1086 in the C-terminal tail strongly suppressed
Y845 phosphorylation37. To address if Y845 phosphorylation
happens via direct trans-phosphorylation or indirectly via
recruitment of a tyrosine kinase to the phosphorylated C-
terminal tail, we investigated Y845 phosphorylation and con-
formational dynamics of a C-terminal tail truncated CONEGI
mutant (CONEGI-ΔD969). This mutant retained its ability to
dimerize (Supplementary Fig. 4g), but was severely impaired in
Y845 phosphorylation (Fig. 4f, Supplementary Fig. 4h). At
saturating EGF dose, CONEGI-ΔD969 followed closely the
conformational dynamics of CONEGI (Fig. 4g; Supplementary
Fig. 4i), consistent with activation by the allosteric dimerization
mechanism. However, at sub-saturating EGF dose, the change in
τ of CONEGI-ΔD969 was signiﬁcantly slower and of lesser
magnitude as compared to that of CONEGI (Fig. 4h; Supple-
mentary Fig. 4i). In fact, C-terminal truncation led to a similar
attenuation of the conformational transition as the Y845F
mutation (compare Fig. 4h to 4d). This shows that C-terminal
auto-phosphorylation on EGFR is necessary to recruit or activate
another tyrosine kinase that activates monomers by trans-
phosphorylation on Y84537. These activated monomers can
phosphorylate EGFR on the C-terminal tail, closing an auto-
catalytic loop.
Discussion
Many insights in the ligand-induced allosteric dimer activation
mechanism of EGFR were gained by structural studies that cap-
tured different conformations of the ECD and the TKD2,5. On the
other hand, genetically encoded optical kinase substrate sensors
provided information about spatially resolved EGFR phosphor-
ylation dynamics26,38, but could not relate EGFR conformational
dynamics to its phosphorylation activity. To bridge this gap, we
developed the conformational sensor CONEGI that reports on
conformational transitions in the activation loop of the EGFR
TKD in living cells, thereby enabling us to relate EGFR’s con-
formation to its phosphorylation activity and dimerization.
We designed multiple CONEGI variants in a hybrid approach
using genetic code expansion in order to detect conformational
dynamics in different key functional regions of the TKD. The
limited availability of membrane-permeable dyes restricted the
selection of an acceptor ﬂuorophore with the spectral properties
to form a FRET pair with mCitrine. This likely explains why
existing conformational, FRET-based EGFR sensors are either
based on protein labeling of the ECD39,40 or on in vitro labeling
of intracellular domains41. The development of approaches to
deliver membrane-impermeable dyes into cells42 or of novel
membrane-permeable ﬂuorophore species, e.g., near-infrared
silicon-rhodamine dyes43 will facilitate the generation of similar
conformational FRET sensors in the future. Here, we proved
BCNK-labeling with the membrane-permeable Atto590 to be
stable and highly speciﬁc in living cells (Fig. 1d, e, g, h). BCNK
incorporation at the individual sites of the EGFR TKD affected
kinase functionality to a different extent. Increased autonomous
phosphorylation of CONEGI-712/713 and -713 might be caused
by perturbation of inhibitory electrostatic interactions of kinase
loop 2 with the PM7. The low EGF-induced fold-change in
phosphorylation of CONEGI-737 could originate from hindrance
of salt bridge formation between K721 and E738 that is essential for
adopting the active conformation9 or from perturbation of the
αC-helix structure. In contrast, BCNK incorporation at position
851 in the activation loop was compatible with kinase function
probably because the activation loop is a highly ﬂexible region
and the incorporation site is sufﬁciently apart from the catalyti-
cally important DFG motif (830–832), Y845 and a β-strand that
turns into a two-turn helix upon activation10.
With CONEGI, we investigated if and by which mechanism
catalytic EGFR activation occurs. The comparison in dimerization
(by ﬂuorescence anisotropy) and conformational transitions in
the activation loop (by FLIM) of CONEGI with its Y845F mutant,
not only showed the conformational transition driven by allos-
teric interactions in EGF-activated EGFR dimers2, but also that
Y845 phosphorylation induces a conformational change in EGFR
monomers. That this conformational transition induced by Y845
phosphorylation leads to a catalytically more active conformation
was apparent from the increased Y1068 auto-phosphorylation on
CONEGI monomers with respect to the CONEGI–Y845F mutant
(Fig. 3e–i).
Oligomerization at sub-saturating EGF dose has been pro-
posed to amplify receptor phosphorylation beyond what is
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expected from liganded EGFR dimers only44. In principle, this
could explain the ampliﬁcation of phosphorylation that we
ascribe to autocatalysis. However, under these conditions, we
detected an equivalent decrease in anisotropy for CONEGI
and its Y845F mutant showing that they exhibited identical
self-association levels. While the dimerization level of the
CONEGI Y845F mutant correlated with half-maximum Y1068
phosphorylation with respect to saturating EGF dose, Y1068
phosphorylation of CONEGI reached ~72% of that at satur-
ating EGF dose (Fig. 4a, c). This difference of ~22% in Y1068
phosphorylation showed that CONEGI dimers can
phosphorylate CONEGI monomers. Furthermore, we could
also show that at high CONEGI expression levels or inhibition
of phosphatases by PV, Y845 phosphorylation induced a cat-
alytically active conformation by displacing the activation
loop that enabled trans-phosphorylation between EGFR
monomers on Y1068. The PV-induced residual conformational
transition in CONEGI-Y845F that correlated with a lower
Y1068 phosphorylation suggests that besides Y845 phosphor-
ylation, additional posttranslational reactions such as ubi-
quitination or interactions with other proteins could
contribute to generate a catalytically competent conformation
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in EGFR monomers. BCNK incorporation at the known ubi-
quitination site K85145 did not alter the phosphorylation
activity of CONEGI (Fig. 2d, e, g), but other ubiquitination
sites (e.g., K843) close to the EGFR activation loop could affect
the conformation of the activation loop and thereby its kinase
activity. However, we previously showed that EGFR mono-
mers are inefﬁciently ubiquitinated15 in line with Y845 phos-
phorylation, being the dominant mechanism for EGFR
phosphorylation ampliﬁcation.
The diminished Y845 phosphorylation and impaired con-
formational transition in C-terminal tail truncated CONEGI-
ΔD969 monomers, further showed that these depend on auto-
phosphorylation of the C-terminal tail (Fig. 4f, h). EGFR auto-
catalysis can therefore occur by an Y845 phosphorylation induced
catalytically active conformation in EGFR monomers that trans-
phosphorylate EGFR monomers on their C-terminal tail. These
auto-phosphorylation events on the C-terminal tail then induce
the recruitment or activation of a tyrosine kinase that phosphor-
ylates Y845 on EGFR monomers, thereby generating a looped
causality that ampliﬁes EGFR phosphorylation. Phosphorylation
of the C-terminal tail by active Y845 phosphorylated monomeric
receptors as well as the phosphorylation of Y845 by C-terminal tail-
associated tyrosine kinases, indicates that the ﬂexible C-terminal
tail can reach the active site of another EGFR monomer, thereby
overcoming the steric hindrance of the tethered inhibitory con-
formation of the ECD5. Src is known to be activated by
C-terminally phosphorylated EGFR and capable of phosphor-
ylating Y84546,47 and therefore likely involved in this autocatalytic
ampliﬁcation on EGFR.
Theoretically, the autocatalytic phosphorylation mechanism
can generate only one collective state in which all receptors are
fully active48. Therefore, the question arises how autocatalytic
activation is regulated by interaction with other enzymatic
activities. We previously demonstrated that continuous vesicular
recycling of EGFR monomers through perinuclear areas with
high protein tyrosine phosphatase (PTP) activity of ER-associated
PTPs, counteracts spontaneous autocatalytic EGFR activation by
Y845 dephosphorylation on recycling receptors15. The spatial
separation of PTP activity from EGFR activity at the PM thereby
provides a means via which cells can suppress autonomous
autocatalytic activation while maintaining responsiveness to EGF.
The collective response properties of EGFR to EGF at the PM
however arise from the autocatalytic property of EGFR in con-
junction with recursive interaction with PTPRG in the form of a
double negative feedback14,36,48,49.
Autocatalytic EGFR activation can lead to full EGFR
phosphorylation at the PM above a threshold EGF
concentration14,50,51. However, EGFR is organized in clusters of
100–200 nm in diameter with up to 250 EGFR monomers33,52,53
limiting the reach of autocatalysis. This could effectively create
nanoscopic systems that can locally sense and robustly respond to
growth factors.
Methods
Antibodies. Rabbit anti-EGFR (western blot 1:1000; 4267, Cell Signaling Tech-
nology, Danvers, MA), goat anti-EGFR (western blot 1:1000; AF231, R&D Systems,
Minneapolis, MN), mouse anti-pY1068 (western blot: 1:1000; immuno-
ﬂuorescence: 1:200; 2236, Cell Signaling Technology), mouse anti-pY845 (western
blot 1:1000; 558381; BD Biosciences, Heidelberg, Germany), mouse anti-
phosphotyrosine (PY72) (western blot 1:730; P172.1, InVivo Biotech Services,
Henningsdorf, Germany), mouse monoclonal anti-α-Tubulin (western blot 1:4000;
Sigma-Aldrich, St. Louis, MO), rabbit anti-GAPDH (western blot 1:1000; 2118,
Cell Signaling Technology), living colors rabbit anti-GFP (western blot 1:1000;
632593, Clontech, Mountain View, CA), IRDye 680 donkey anti-mouse IgG
(western blot 1:10,000; LI-COR Biosciences, Lincoln, NE), IRDye 800 donkey anti-
rabbit IgG (western blot 1:10,000; LI-COR Biosciences), Alexa Fluor® 647 donkey
anti-mouse IgG (immunoﬂuorescence 1:200; Thermo Fisher Scientiﬁc Inc.,
Waltham, MA).
Plasmids. Restriction and ligation enzymes were purchased from New England
Biolabs (NEB, Frankfurt am Main, Germany). mCitrine-N1, mCherry-N1, and
mTurquoiseN1 were generated by insertion of AgeI/BsrgI PCR fragments of
mCitrine, mCherry, and mTurquoise cDNA in pEGFP-C1 (Clontech, Mountain
View, CA). Fusions of EGFR and PTB domain with ﬂuorescent proteins were
generated through restriction-ligation of EGFR and PTB domain cDNA into the
appropriate vector. To generate EGFR-QG-mCitrine, mCitrine ﬂanked with a
linker sequence (LAAAYSSILSSNLSSDS-mCitrine-SDSSLNSSLISSYAAAL) was
inserted between Q958 and G959 of EGFR. Site-directed mutagenesis PCR using
PfuUltra high-ﬁdelity DNA polymerase (Agilent Technologies, Santa Clara, CA)
replaced coding sequences in EGFR-QG-mCitrine with an amber codon (TAG)
to generate BCNK incorporation sites and was also used to generate the
CONEGI-Y845F mutant. NotI/NheI EGFR(TAG)-QG-mCitrine PCR fragments
were inserted in a (U6-PylT*)4/EF1α plasmid previously described in ref. 23. The
BCNK incorporation system consists of two plasmids, (U6-PylT*)4/EF1α-PylRS
to express the tRNA synthetase and peRF1(E55D) for expression of a modiﬁed
eukaryotic release factor 1 (eRF1). peRF1(E55D) was described earlier23 and
(U6-PylT*)4/EF1α-PylRS was modiﬁed by adding a nuclear export sequence
(NES) LALKLAGLDIGS attached via a ﬂexible 4× (SGGGGS) linker to the N-
terminus of PylRS. The plasmid was created from a previously reported con-
struct54 by inverse PCR followed by insertion of the 4× (SGGGGS) linker via
blunt end ligation. A complete list with all relevant primers is provided in
Supplementary Table 2. All constructs were sequence veriﬁed and tested for
correct expression.
Reagents. Human EGF (Peprotech, Hamburg, Germany) was shock frozen at a
concentration of 100 μg ml−1 in PBS+ 0.1% BSA and stored at −80 °C. Perva-
nadate was freshly prepared by adding sodium orthovanadate (S6508, Sigma-
Aldrich) to H2O2 (30%) according to ref. 30. BCNK was described earlier in ref. 24.
Site-speciﬁc C-terminal labeling of hEGF with Alexa647-maleimide (Life Tech-
nologies, Darmstadt, Germany) was carried out as described in ref. 55. Brieﬂy, the
His-CBD-Intein-(Cys)-hEGF-(Cys) plasmid (kindly provided by Professor Luc
Brunsveld, University of Technology, Eindhoven), was expressed in Escherichia coli
BL21 (DE3) and protein was puriﬁed by Ni-NTA afﬁnity chromatography from
inclusion bodies. Puriﬁed protein was refolded in vitro, followed by intein splicing
and size exclusion chromatography. This puriﬁed human EGF was then C-
terminally labeled with a ﬁvefold molar excess of Alexa647-maleimide, excess dye
was removed by dialysis, and the labeled protein stored in PBS at −20 °C. Tet-
Atto590 was synthesized by conjugating Atto590-NHS ester (79636, Sigma-
Aldrich) to tet-NH2 in the presence of N,N-Diisopropylethylamine (DIPEA). The
product was puriﬁed using high-performance liquid chromatography (HPLC) and
Fig. 4 EGFR dimers can induce autocatalytic activation of EGFR monomers. a Relative Y1068 phosphorylation (pY1068/CONEGI) of CONEGI and CONEGI-
Y845F upon stimulation with 100 ngml−1 EGF by western blot analysis (n= 4; two-way ANOVA) (Supplementary Fig. 4b). b Change in Δτ of CONEGI and
CONEGI-Y845F at the PM (upper panel) upon stimulation with 100 ngml−1 EGF and the difference (ΔΔτ) between CONEGI and CONEGI-Y845F (lower
panel) (CONEGI: n= 19 cells; Y845F: n= 8) (Supplementary Fig. 4d). c Relative Y1068 phosphorylation (pY1068/CONEGI) of CONEGI and CONEGI-Y845F
upon stimulation with 20 ngml−1 EGF by western blot analysis (n= 4; two-way ANOVA) (Supplementary Fig. 4b). d Change in Δτ of CONEGI and
CONEGI-Y845F at the PM upon stimulation with 20 ngml−1 EGF (upper panel) and the difference (ΔΔτ) between CONEGI and CONEGI-Y845F (lower
panel) (CONEGI: n= 6 cells; Y845F: n= 7; two-way ANOVA) (Supplementary Fig. 4e). e Relative Y845 phosphorylation (pY845/CONEGI) of CONEGI upon
stimulation with 20 and 100 ngml−1 EGF by western blot analysis (n= 3) (Supplementary Fig. 4f). f Relative Y845 phosphorylation (pY845/CONEGI) of
CONEGI and CONEGI-ΔD969 upon stimulation with 100 ngml−1 EGF by western blot analysis (n= 3; unpaired two-tailed t-test) (Supplementary Fig. 4h).
g, h Change in Δτ of CONEGI-ΔD969 and CONEGI at the PM upon stimulation with 20 (h) and 100 ngml−1 EGF (g) (upper panel) and the difference
(ΔΔτ) between CONEGI and CONEGI-ΔD969 (lower panel) (CONEGI: 20 ngml−1 EGF: n= 6 cells; 100 ngml−1 EGF: n= 19; ΔD969: 20 ngml−1 EGF:
n= 9; 100 ngml−1: n= 6; two-way ANOVA) (Supplementary Fig. 4i). Error bars: SEM. τ ﬂuorescence lifetime of mCitrine
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06299-7
10 NATURE COMMUNICATIONS |  (2018) 9:3847 | DOI: 10.1038/s41467-018-06299-7 | www.nature.com/naturecommunications
the identity of the compound conﬁrmed by mass spectroscopy. Lapatinib (231277-
92-2, Cayman Chemical, Ann Arbor, MI) was solubilized in ethanol to a stock
concentration of 10 mM and stored at 4 °C.
Crystal structure. PDB ﬁles of crystal structures of the active and inactive EGFR
TKD were downloaded from the RSCB protein data bank. Alignment of the crystal
structures and measurement of the distances between insertion sites were per-
formed using the program MacPyMOL (http://www.pymol.org).
Cell culture and site-speciﬁc labeling. Identities of HEK293T (ATCC: CRL-
11268), MCF10A (ATCC: CRL-10317), and A431 (DSMZ: ACC91) cells were
determined by DNA proﬁling using eight different and highly polymorphic short
tandem repeat (STR) loci and testing for the presence of mitochondrial DNA
sequences from rodent cells as mouse, rat, chinese and syrian hamster (DSMZ) and
tested regularly for mycoplasma contamination using MycoAlert Mycoplasma
detection kit (Lonza). MCF10A cells were grown in DMEM/F12 media supple-
mented with 5% horse serum, 20 ng ml−1 EGF, 0.5 μg ml−1 hydrocortisone
(H-0888, Sigma-Aldrich), 100 ng ml−1 cholera toxin (Sigma-Aldrich), 10 μg ml−1
insulin (Sigma-Aldrich), and 1% glutamine and maintained at 37 °C in 5% CO2.
A431 and HEK293T cells were grown in Dulbecco’s Modiﬁed Eagle’s Medium
(DMEM) supplemented with 10% fetal bovine serum, 2 mM L-glutamine and 1%
non-essential amino acids (NEAAs) and maintained at 37 °C in 5% CO2. Trans-
fection of mammalian cells with plasmid DNA was achieved using Fugene®6
according to the manufacturers protocol. HEK293T cells in one well of an eight-
well Labtek (for confocal microscopy and FLIM) were transfected with 250 ng of
the EGFR expression plasmid, 100 ng (U6-PylT*)4/EF1α-PylRS and 100 ng peRF1
(E55D). Cells in one well of a 24-well dish (for western blot analysis) were
transfected with 500 ng of the EGFR expression plasmid, 100 ng (U6-PylT*)4/
EF1α-PylRS, and 100 ng peRF1(E55D). HEK293T cells in MatTeks (for anisotropy)
were transfected with 1000 ng of the EGFR expression plasmid, 100 ng (U6-
PylT*)4/EF1α-PylRS, and 100 ng peRF1(E55D). Media was replaced by fresh media
supplemented with 1 mM BCNK before addition of the transfection mix to cells.
Cells were incubated overnight at 37 °C with 5% CO2 and BCNK was washed out
on the next day. Labeling was performed using 400 nM tet-Atto590 in DMEM for
20 min at room temperature (RT). The washout of free diffusing tet-Atto590 was
carried out for at least 2 h with media exchange every 15–20 min.
Western blotting and in-gel ﬂuorescence. Cells were lysed in ready-made cell
lysis buffer (9803, Cell Signaling Technology) supplemented with Complete Mini
EDTA-free protease inhibitor (Roche Applied Science, Heidelberg, Germany) and
100 μl phosphatase inhibitor cocktail 2 and 3 (P5726 and P0044, Sigma-Aldrich).
Following lysis, samples were cleared by centrifugation for 10 min, 13,000 r.p.m.
at 4 °C. Bis-Tris-PAGE was performed using the X-cell II mini electrophoresis
apparatus (Life Technologies) according to the manufacturer’s instructions. Pro-
teins were transferred to preactivated polyvinylidene diﬂuoride (PVDF) mem-
branes (Merck Chemicals, Darmstadt, Germany) and incubated with the respective
primary antibodies at 4 °C overnight. Detection was performed using species-
speciﬁc IR-Dye 800 CW and IR-Dye 680 secondary antibodies (LI-COR Bios-
ciences, Bad Homburg vor der Höhe, Germany) and the Odyssey Infrared Imaging
System (LI-COR Biosciences). Eventually, Bis-Tris gels were imaged with the
Typhoon Trio Variable Mode Imager (GE Healthcare, Buckinghamshire, UK) to
detect ﬂuorescently labeled proteins before western blotting. Atto590 was excited
using a 532 nm laser and ﬂuorescence emission was detected with a 610/30 BP ﬁlter
at a resolution of 100 μm. Uncropped western blots and in-gel ﬂuorescence images
are shown in Supplementary Fig. 5.
Immunoﬂuorescence. Cells were ﬁxed with 4% paraformaldehyde (Roti®-Histoﬁx
4%, Carl Roth GmbH, Karlsruhe, Germany) for 10min at RT and permeabilized for
5 min with 0.1% Triton X-100 in TBS. Background staining was blocked by incu-
bation with Odyssey® Blocking Buffer (LI-COR Biosciences) for 1 h at 4 °C. Primary
antibodies diluted in Odyssey® Blocking Buffer were applied overnight at 4 °C and
secondary antibodies for 1 h at RT. Fixed cells were imaged in TBS at 37 °C. In
background-subtracted images, masks for the PM of single cells were generated and
the mean ﬂuorescence intensity for each channel was measured in ImageJ (http://
imagej.nih.gov/ij/). The relative phosphorylation on Y1068 was determined per cell
and the mean values of Y1068/EGFR-QG-mCitrine variants were calculated.
Fluorescence microscopy. Confocal images at the Olympus FV1000 equipped
with a 60×/1.35 numerical aperture Oil UPLSApo objective (Olympus, Hamburg,
Germany) and a temperature controlled incubation chamber (EMBL, Heidelberg,
Germany) were acquired in sequential mode frame by frame with 2× line aver-
aging. The pinhole was set to 2.5 airy units. mCitrine was excited with a 488 nm
Argon laser (GLG 3135, Showa Optronics, Tokyo, Japan), mCherry/Atto590 with a
561 nm DPPS laser (85-YCA-020-230, Melles Griot, Bensheim, Germany), and
Alexa647 with a 633 HeNe laser (05LHP-991, Melles Griot, Bensheim, Germany)
using a DM405/488/561/633 dichroic mirror. mCitrine ﬂuorescence was detected
between 498 and 551 nm using the SDM560 beam splitter. Atto590/mCherry
ﬂuorescence was detected in the bandwidth of 575–675 nm and Alexa647 ﬂuor-
escence between 643 and 743 nm. With these settings, no bleed through between
mCitrine and Atto590 or mCherry was observed. Live cells were imaged in imaging
media at 37 °C and 5% CO2 and stimulated with 20 ng ml−1 EGF, 100 ng ml−1
EGF, or 0.33 mM PV.
Fluorescence lifetime imaging microscopy. FLIM data were obtained with the
Olympus FV1000 laser scanning microscope (Olympus) equipped with an external
unit, PicoQuant’s compact FLIM and FCS upgrade kit laser scanning microscopes
(Picoquant GmbH, Berlin, Germany) using a 60×/1.35 NA Oil UPLSApo objective
(Olympus). Pulsed lasers were coupled to the FV1000 through an independent port
and controlled with SepiaII software (Picoquant GmbH). Detection of photons was
achieved using a single photon avalanche diode (PDM Series, MPD, Picoquant
GmbH) and timed using a single photon counting module (PicoHarp 300, Pico-
quant GmbH). Using the SymPhoTime software V5.13 (Picoquant GmbH) images
were collected with an integration time of ~2 min collecting ~3.0–5.0 × 106 pho-
tons. mCitrine was excited by a 507 nm pulsed laser with an average power of
0.025 mW on the sample (LDH 507, Picoquant GmbH) and ﬂuorescence of
mCitrine was collected using a narrow-band emission ﬁlter (HQ 537/26, Chroma,
Olching, Germany). FLIM data were analyzed using the global analysis code
described in ref. 56 to obtain images of the mean ﬂuorescence lifetime τ. Pixels with
<50 counts were excluded from analysis. To measure the ﬂuorescence lifetime at
periphery of each cell that mostly encompasses the PM, we ﬁrst derived whole cell
masks, which were then eroded by 10 pixels. From the ‘XOR’ operation of the two
masks, we obtained the 10-pixel wide peripheral masks from which the mean
ﬂuorescence lifetime τ was determined. Image processing was performed in ImageJ
(http://imagej.nih.gov/ij/).
Wideﬁeld anisotropy. Anisotropy microscopy was performed on an Olympus
IX81 inverted microscope (Olympus) equipped with a 20×/0.7 NA air objective
using an Orca CCD camera (Hamamatsu Photonics, Hamamatsu City, Japan) and
an incubation chamber (EMBL). mCitrine and Atto590 were excited using a MT20
illumination system. The conversion factor (electrons per digital) was determined
to be 6.7 taking into account the quantum yield of the Orca CCD camera. A linear
dichroic polarizer (Meadowlark optics, Frederick, CO) was implemented in the
illumination path of the microscope, and two identical polarizers were placed in an
external ﬁlter wheel at orientations parallel and perpendicular to the polarization of
the excitation light. For each ﬁeld of view two images were taken, one with the
emission polarizer oriented parallel to the excitation polarizer Ik
 
and one with
the emission polarizer oriented perpendicular to the excitation polarizer I?ð Þ. The
ﬂuorescence anisotropy (ri) in each pixel i was calculated according to:
ri ¼
GiIk  I?
GiIk þ 2I?
: ð1Þ
To determine the G-factor (Gi), parallel and perpendicular images of the ﬂuor-
ophore ﬂuorescein were taken in solution. Fluorescein’s anisotropy is close to zero
and therefore allows calculating Gi by building the ratio of the perpendicular over
the parallel intensities. Fluorescence anisotropy was calculated per pixel as we
expected a heterogeneous distribution of the ﬂuorescence anisotropy within cells.
To avoid bleaching only one parallel and one perpendicular image was taken, no
smoothing was applied. The mean anisotropy ± SEM for binned mCitrine inten-
sities were taken over multiple ﬁelds of view. The range of mCitrine intensity bins
(1000–1800 counts) corresponded to PM localized EGFR. Every ﬁeld of view
contained ~5–10 cells. The CellR software supplied by the microscope manu-
facturer (Olympus) controlled data acquisition. Live cells were imaged in vitamin-
free media at 37 °C and 5% CO2 and stimulated with either 100 ng ml−1 EGF or
0.33 mM PV.
Quantifying CONEGI expression level. In order to determine the expression level
of CONEGI in HEK293T cells, EGF-Alexa647 (100 ng ml−1) was administered to
A431, MCF10A, and CONEGI-expressing HEK293T cells. The amount of bound
EGF-Alexa647 per cell was determined by measuring the ﬂuorescence intensity
with confocal ﬂuorescence microscopy for individual cells and integrating the
intensity post-acquisition per cell. From these data, ﬂuorescence intensity histo-
grams were generated that represent the relative expression levels of EGFR and
CONEGI in the respective cells (Supplementary Fig. 3k). In order to determine the
expression level of CONEGI in HEK293T cells at which phosphorylation ampli-
ﬁcation occurs, the median of the EGF-Alexa647 ﬂuorescence distribution was
matched to that of the mCitrine ﬂuorescence per cell distribution obtained from
immunoﬂuorescence (Fig. 3g). Assuming that MCF10A cells express 105 receptors
per cell and A431 cells 106 receptors per cell allowed the estimation of CONEGI
expression, which was in the range of 2–5 × 105 receptors per cell.
Statistical analysis. All results are expressed as mean ± SEM or in Tukey box
plots. Statistical analysis was performed with GraphPad Prism, version 6.0e for Mac
(GraphPad Software, La Jolla, CA, USA). Statistical signiﬁcance was estimated
either by paired or unpaired two-tailed t-tests or by two-way analysis of variance.
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